Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pharma Execs Say Senate Drug Pricing Bill Targets Industry, Not The Problem
Industry CEOs expressed reservations about the US drug pricing legislation in the Senate, but said they support reforms that will impact patient affordability, during Q2 calls.
Latest From Pricing Debate
Patent “March-In” As Price Control Draw Little Support At US National Academies Meeting
The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.
Can’t Let Go: HHS Seeks To Overturn US Court Decision Striking Down DTC Ad Rule
The appeal is in keeping with the President Trump’s plan to stay active on drug pricing initiatives so he can claim victory on a key campaign promise.
In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
In Search Of Goodwill, Several Pharmas Commit To New Corporate ‘Statement Of Purpose’
The updated business principles may give pharma companies leverage, or at least talking points, as they continue to engage with the Trump administration on policies like the International Pricing Index and with US lawmakers on drug pricing legislation. J&J's Gorsky heads governing committee of multi-industry business group that revised its principles.
Canadian Drug Pricing Reforms Could Lead To Medicine Shortages
Drug pricing reform in Canada could prompt companies to launch elsewhere or see drugs diverted to the US.
GAO Report On Part D May Dampen Congressional Enthusiasm For POS Rebates
Legislation redirecting manufacturer rebates on prescription drugs to the point of sale could face an uphill battle following report’s description of the way rebates lower costs in Medicare Part D.
Canada Overhauls Drug Pricing, But Devil Will Be In The Detail
Long awaited changes to Canada’s Patented Medicines Regulations have been announced, but companies will have to wait for new guidelines from the pricing watchdog to better understand how they will be implemented.
Beyond The "Blueprint": The Next Stage For US HHS Drug Price Policy
Upcoming transition in HHS drug pricing policy staff reinforces the Trump Administration's shift away from the 2018 "Blueprint” and towards engaging with bipartisan Congressional legislation – and spotlighting executive action as coming from the White House in the context of the upcoming Presidential campaign.
Descovy, Truvada And The Politics Of PrEP
US FDA's advisory committee review of Gilead’s Descovy for pre-exposure prophylaxis of HIV wasn’t exactly free of controversy. But the meeting sure went more smoothly than the first PrEP review seven years ago.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.